Alumis Inc. to Present at Multiple Investor Conferences in September 2026

SOUTH SAN FRANCISCO, Calif., Sept. 04, 2026 /CourierPR/ -- Alumis Inc., a late-stage biopharmaceutical company developing advanced treatments for immune-mediated diseases, will participate in several key investor conferences in September 2026. The company will present at the Wells Fargo 21st Annual Healthcare Conference in Boston and the Cantor Global Healthcare Conference and Morgan Stanley Global Healthcare Conference in New York. Additionally, Alumis will present at the Baird 2026 Global Healthcare Conference in New York.

At the Wells Fargo conference, scheduled for September 8-10, 2026, an Alumis representative will deliver a fireside chat at 11:00 am Eastern Time. On September 9, 2026, Alumis will participate in the Cantor Global Healthcare Conference, with a fireside chat set for 2:10 pm Eastern Time. The Morgan Stanley Global Healthcare Conference, also in New York, will feature an Alumis presentation on Monday, September 14, 2026, at 7:45 am Eastern Time. Finally, the Baird 2026 Global Healthcare Conference on September 15, 2026, will include a company presentation at 10:15 am Eastern Time.

Investors can access live webcasts of these events through the “Events” page on the “Investors” section of the Alumis website. Webcast replays will be available on the company’s website for 90 days.

Alumis Inc. is at the forefront of developing next-generation targeted therapies. The company’s pipeline includes envudeucitinib, previously known as ESK-001, for systemic immune-mediated disorders such as moderate-to-severe plaque psoriasis and systemic lupus erythematosus, and A-005, a central nervous system penetrant TYK2 inhibitor, initially targeting Parkinson’s disease. Additional indications for A-005 are under evaluation.